Genes and Patents: Evolution; Controversies and Perspectives
|発行||Technical Insights (Frost & Sullivan)||商品コード||307110|
|出版日||ページ情報||英文 56 Pages
|遺伝子と特許：進化；議論および展望 Genes and Patents: Evolution; Controversies and Perspectives|
|出版日: 2014年06月30日||ページ情報: 英文 56 Pages||
当レポートでは、遺伝子特許分野について取り上げ、遺伝子特許のメリット、歴史、問題および生命倫理、米国におけるAssociation For Molecular Pathology v. Myriad Genetics 事件と米最高裁の判断、Myriad Rulingの影響などについて、詳細を明らかにしています。
Who owns our genes?
Genes are the constituent elements of a human body. Genetic research has been carried out to find answers to several questions pertaining to diseases, drug discovery, diagnostics and therapeutics. It is an expensive mode of research and development. As a result, many researchers and developers see the need to secure intellectual property protection by means of patents. This not only secures their expensive invention from being duplicated elsewhere but also provides collateral for funding. But genetic patenting has been in news for quite some time. For many, it is difficult to fathom how a third party can claim ownership over ones genes. Moreover, patenting restricts access to knowledge which in turn provides a setback to the research community. In the light of the above mentioned, the United States Supreme Court deliberated on the celebrated case of Association for Molecular Pathology v. Myriad Genetics. The decision changed to quite an extent the patent eligibility requirements for a naturally occurring gene. It left several previously granted patents vulnerable to be invalidated. The United States Patent and Trademarks Office laid down guidelines for examination of such patent applications, post this decision. The research service highlights such details in the field of gene patenting.